Lead therapeutic candidate MOv18 IgE is the world’s first IgE drug to enter clinical trials.
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, hosted a Key Opinion Leader (KOL) webinar for the investment community on its IgE platform on Monday, June 29, 2020 at 11am ET (4pm BST).